All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Amgen, Autolus, Jazz Pharmaceuticals, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View ALL content recommended for you
AALL1731 trial: Blinatumomab + chemotherapy in pediatric patients with SR B-ALL
Do you know... Based on the updated results from the AALL1731 trial, what was the impact on adverse prognostic factors when blinatumomab was added to chemotherapy vs chemotherapy alone?
The randomized phase III AALL1731 (NCT03914625) trial assessed the efficacy and safety of adding blinatumomab and alternating with chemotherapy vs chemotherapy alone in the first-line consolidation phase in the treatment of pediatric patients aged 1 year to <10 years with newly diagnosed Philadelphia-chromosome negative (Ph−) standard-risk (SR) B-cell acute lymphoblastic leukemia.1
At the first efficacy interim analysis, with a median 2.5 years of follow-up, which included 1,440 randomized patients, data indicated a disease-free survival benefit with the addition of blinatumomab to chemotherapy, and randomization was stopped early.1 Results from this trial were published in the New England Journal of Medicine by Gupta et al.1 Updated results, with a median 3.5 years of follow-up, were presented by Gupta during the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, and demonstrated that the benefit of blinatumomab + chemotherapy was sustained in this patient population.2
This educational resource is independently supported by Amgen. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
